Right lobe living donors ages 55 years old and older in liver transplantation

Seong Hoon Kim, Eung Chang Lee, Jae Ryong Shim, Sang Jae Park – 22 July 2017 – The evidence is insufficient for safe use of elderly donors in adult‐to‐adult living donor liver transplantation (LDLT). The aim of this study was to evaluate the outcomes of right lobe LDLT by donor age (≥55 versus < 55 years). All living donors who underwent right hepatectomy at the authors’ institution between March 2008 and December 2015 were divided into 2 groups: group A with an age ≥ 55 years and group B with an age of <55 years.

A systematic review and meta‐analysis of cold in situ perfusion and preservation of the hepatic allograft: Working toward a unified approach

Ahmer M. Hameed, Jerome M. Laurence, Vincent W. T. Lam, Henry C. Pleass, Wayne J. Hawthorne – 22 July 2017 – The efficacy of cold in situ perfusion and static storage of the liver is a possible determinant of transplantation outcomes. The aim of this study was to determine whether there is evidence to substantiate a preference for a particular perfusion route (aortic or dual) or perfusion/preservation solution in donation after brain death (DBD) liver transplantation. The Embase, MEDLINE, and Cochrane databases were used (1980‐2017).

Programmed cell death‐1 (PD‐1) checkpoint blockade in combination with a mammalian target of rapamycin inhibitor restrains hepatocellular carcinoma growth induced by hepatoma cell–intrinsic PD‐1

Hui Li, Xiaoqiang Li, Shuang Liu, Lei Guo, Bo Zhang, Jubo Zhang, Qinghai Ye – 21 July 2017 – Inhibitors of programmed cell death 1 (PD‐1) administered as single agents have resulted in durable tumor regression in advanced cancer patients. However, only a minority of cancer patients respond to anti‐PD‐1 immunotherapy. Here, we show that PD‐1 expression in hepatocellular carcinoma promotes tumor growth independently of adaptive immunity. Knockdown of PD‐1 suppresses tumor growth, whereas PD‐1 overexpression enhances tumorigenesis in immunodeficient xenografted mice.

Transforming growth factor‐β in liver cancer stem cells and regeneration

Shuyun Rao, Sobia Zaidi, Jaideep Banerjee, Wilma Jogunoori, Raul Sebastian, Bibhuti Mishra, Bao‐Ngoc Nguyen, Ray‐Chang Wu, Jon White, Chuxia Deng, Richard Amdur, Shulin Li, Lopa Mishra – 21 July 2017 – Cancer stem cells have established mechanisms that contribute to tumor heterogeneity as well as resistance to therapy. Over 40% of hepatocellular carcinomas (HCCs) are considered to be clonal and arise from a stem‐like/cancer stem cell.

Subscribe to